All In Biotech

Drug Trial Radar · NCT06911216

A Pharmacokinetics (PK) Study in Healthy Adults

A Multiple-Dose Pharmacokinetics (PK) Study of STN1013800 in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Mar 17, 2025

Primary completion

Apr 7, 2025

Study completion Apr 7, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is to characterize STN1013800 active ingredient bioavailability following multiple-dose ocular administration of STN1013800 to both eyes in healthy adults. It is a PK study with screening period of up to 28 days + dosing period of 7 days + Follow-up period of 2 days. At present, there are no medicines for the treatment of acquired blepharoptosis in China. Therefore, efficacy and safety phase III study is also currently being conducted.

Conditions

  • Blepharoptosis

Interventions

  • STN1013800 ophthalmic solutionDrug

    Investigational Product: 0.1% STN1013800 ophthalmic solution once daily (QD) (9AM ± 60 min), one drop for each eye

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK (Pharmacokinetic) parameter to measure: CmaxTime frame: Day 1, 5, 6, and 7
  2. PK parameter to measure: CminTime frame: Day 1, 5, 6, and 7
  3. PK parameter to measure: TmaxTime frame: Day 1, 5, 6, and 7
  4. PK parameter to measure: AUC0-24hTime frame: Day 1, 5, 6, and 7
  5. PK parameter to measure: AUC0-36hTime frame: Day 1, 5, 6, and 7
  6. PK parameter to measure: AUCinfTime frame: Day 1, 5, 6, and 7
  7. PK parameter to measure: kelTime frame: Day 1, 5, 6, and 7
  8. PK parameter to measure: t½Time frame: Day 1, 5, 6, and 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital, Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.